IL243362A0 - Use of sigma receptor ligands for the prevention and treatment of pain associated with interstitial/cystitis bladder pain syndrome (ic/bps) - Google Patents

Use of sigma receptor ligands for the prevention and treatment of pain associated with interstitial/cystitis bladder pain syndrome (ic/bps)

Info

Publication number
IL243362A0
IL243362A0 IL243362A IL24336215A IL243362A0 IL 243362 A0 IL243362 A0 IL 243362A0 IL 243362 A IL243362 A IL 243362A IL 24336215 A IL24336215 A IL 24336215A IL 243362 A0 IL243362 A0 IL 243362A0
Authority
IL
Israel
Prior art keywords
bps
prevention
treatment
receptor ligands
interstitial cystitis
Prior art date
Application number
IL243362A
Other languages
English (en)
Hebrew (he)
Inventor
Vela-Hernandez Jose-Miguel
Merlos-Roca Manuel
Baeyens-Cabrera Jose-Manuel
Cendan-Martinez Cruz-Miguel
Original Assignee
Esteve Pharmaceuticals Sa
Jose Miguel Vela Hernandez
Manuel Merlos Roca
Jose Manuel Baeyens Cabrera
Cruz Miguel Cendan Martinez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa, Jose Miguel Vela Hernandez, Manuel Merlos Roca, Jose Manuel Baeyens Cabrera, Cruz Miguel Cendan Martinez filed Critical Esteve Pharmaceuticals Sa
Publication of IL243362A0 publication Critical patent/IL243362A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL243362A 2013-06-26 2015-12-27 Use of sigma receptor ligands for the prevention and treatment of pain associated with interstitial/cystitis bladder pain syndrome (ic/bps) IL243362A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382246.0A EP2818166A1 (en) 2013-06-26 2013-06-26 Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
PCT/EP2014/063360 WO2014207024A1 (en) 2013-06-26 2014-06-25 Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)

Publications (1)

Publication Number Publication Date
IL243362A0 true IL243362A0 (en) 2016-02-29

Family

ID=48700506

Family Applications (1)

Application Number Title Priority Date Filing Date
IL243362A IL243362A0 (en) 2013-06-26 2015-12-27 Use of sigma receptor ligands for the prevention and treatment of pain associated with interstitial/cystitis bladder pain syndrome (ic/bps)

Country Status (19)

Country Link
US (1) US20160151377A1 (enExample)
EP (2) EP2818166A1 (enExample)
JP (1) JP2016523276A (enExample)
KR (1) KR20160023839A (enExample)
CN (1) CN105377257A (enExample)
AR (1) AR096709A1 (enExample)
AU (1) AU2014301220A1 (enExample)
BR (1) BR112015032343A8 (enExample)
CA (1) CA2916568A1 (enExample)
HK (1) HK1221656A1 (enExample)
IL (1) IL243362A0 (enExample)
MA (1) MA38711A1 (enExample)
MX (1) MX2015017761A (enExample)
PH (1) PH12015502815A1 (enExample)
RU (1) RU2016102149A (enExample)
SG (1) SG11201510408XA (enExample)
TN (1) TN2015000558A1 (enExample)
TW (1) TWI629984B (enExample)
WO (1) WO2014207024A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
MX2016007286A (es) * 2013-12-17 2016-08-04 Esteve Labor Dr Combinaciones de gabapentinoides y ligandos de receptores sigma.
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
KR20250116520A (ko) 2024-01-25 2025-08-01 가톨릭대학교 산학협력단 칸나비디올을 유효성분으로 포함하는 방광 통증 증후군의 예방 또는 치료용 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335668B2 (en) * 2001-07-10 2008-02-26 Astellas Pharma Inc. Pharmaceutical composition for therapy of interstitial cystitis
KR101352012B1 (ko) 2004-08-27 2014-01-15 라보라토리오스 델 드라. 에스테브.에스.에이. 시그마 수용체 저해제
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
US20090325975A1 (en) * 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
CN101395157A (zh) * 2006-03-01 2009-03-25 伊斯特芬博士实验室有限公司 作为西格玛受体抑制剂的吡唑衍生物
WO2007098953A1 (en) * 2006-03-01 2007-09-07 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2353591A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2460519A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
EP2460804A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del Dr. Esteve, S.A. 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
NZ618795A (en) * 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain

Also Published As

Publication number Publication date
AU2014301220A1 (en) 2016-02-18
BR112015032343A2 (pt) 2017-09-26
BR112015032343A8 (pt) 2018-01-23
EP3013338A1 (en) 2016-05-04
SG11201510408XA (en) 2016-01-28
MA38711A1 (fr) 2017-12-29
WO2014207024A1 (en) 2014-12-31
TWI629984B (zh) 2018-07-21
CA2916568A1 (en) 2014-12-31
RU2016102149A (ru) 2017-08-02
US20160151377A1 (en) 2016-06-02
TW201536295A (zh) 2015-10-01
KR20160023839A (ko) 2016-03-03
RU2016102149A3 (enExample) 2018-05-25
TN2015000558A1 (en) 2017-04-06
CN105377257A (zh) 2016-03-02
HK1221656A1 (zh) 2017-06-09
MX2015017761A (es) 2016-07-06
JP2016523276A (ja) 2016-08-08
AR096709A1 (es) 2016-01-27
EP2818166A1 (en) 2014-12-31
PH12015502815A1 (en) 2016-03-21

Similar Documents

Publication Publication Date Title
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
SG11201510408XA (en) Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)
EP2983657A4 (en) TREATMENT OF GASTROINTESTINAL AND OTHER DISEASES
IL244014A0 (en) Combined therapy for the treatment of glioblastoma
EP3068289A4 (en) Prevention and treatment of bed exits, falls, and other conditions
PL3811943T3 (pl) Związek do stosowania w leczeniu zaburzeń oczu
ZA201702410B (en) Sodium channel modulators for the treatment of pain and diabetes
GB201307047D0 (en) Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
PL3004108T3 (pl) Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
EP2952149A4 (en) THERAPEUTIC TREATMENT DEVICE
AU354694S (en) Surface treatment pad
AU355851S (en) Surface treatment and cleaning pad
EP2949274A4 (en) HEART TREATMENT DEVICE
PT3074033T (pt) Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
GB201309645D0 (en) Treatment of peripheral arterial disease and other conditions, and apparatus therefor
GB201320506D0 (en) Cyclic amino compounds for the use in the treatment of cardiac disorders
HUE036306T2 (hu) Odiparcil alkalmazása mukopoliszacharidózis kezelésében
GB201410954D0 (en) Skin treatment devices and methods